STOCKS TELEGRAPH

Tag: Predictive Oncology

  • Predictive Oncology (POAI) Stock Surges Following Major Drug Discovery Breakthrough

    Predictive Oncology (POAI) Stock Surges Following Major Drug Discovery Breakthrough

    As of the most recent check today, Predictive Oncology Inc. (NASDAQ: POAI) shares were significantly rising 69.58% to $1.89. A notable advancement in creating a new compound in partnership with the Natural Products Discovery Core (NPDC) at the University of Michigan drove that momentum.

    A Successful Collaboration with the University of Michigan

    Predictive Oncology has partnered with the NPDC at the Life Sciences Institute at the University of Michigan to advance drug discovery. Applying Predictive’s state-of-the-art machine learning technology, which has proven successful in predicting the efficacy of possible drugs, is the main goal of the collaboration. To expedite the screening procedure and improve the likelihood of success, this platform makes use of a sizable biobank of live-cell tumor samples.

    Novel Approaches to Cancer Treatment Using Natural Products

    The NPDC has one of the largest natural products libraries in the United States, including specimens from biodiversity hotspots across the globe. Numerous authorized small-molecule medications have been generated from natural chemicals, which have historically played a significant role in drug development.

    Three of the 21 new chemicals that Predictive Oncology evaluated showed consistently robust anti-tumor responses across a variety of cancer types, surpassing the effectiveness of the well-known chemotherapeutic medication doxorubicin.

    Machine Learning to Speed Up Drug Discovery

    Promising results were obtained by evaluating these chemicals on models of ovarian, colon, and breast cancer. Using only 7% of the potential wet lab experiments, POAI’s machine learning model successfully predicted outcomes for 73% of all possible tests. This significant reduction in experimental time could potentially eliminate up to two years of traditional lab testing.

    Future Prospects and Further Investigations

    By examining only 1% of the NPDC’s accessible chemicals, the partnership produced encouraging results that open the door for more research. The NPDC anticipates growing their collaboration with Predictive Oncology (POAI), investigating other substances, and disseminating the results of these continuing investigations.

  • Predictive Oncology (POAI) Shares Surge Following Strategic Expansion Announcement

    Predictive Oncology (POAI) Shares Surge Following Strategic Expansion Announcement

    After announcing a strategic expansion, Predictive Oncology Inc. (NASDAQ: POAI) has seen its shares gain significant momentum during the current market session. As of the latest check, POAI stock has surged by 109.35%, trading at $2.24 on the US stock charts.

    Predictive Oncology Expanding Through AI/ML Driven Drug Discovery Platform

    With the intention of finding novel biomarkers that can predict patient outcomes and treatment responses in cancer, Predictive Oncology has disclosed its ambitions to improve its AI/ML-driven drug development platform. In partnership with UPMC Magee-Womens Hospital, a retrospective investigation on ovarian cancer produced findings that served as inspiration for this biomarker identification project.

    The results were showcased at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO). Compared to clinical data alone, Predictive Oncology’s multi-omic machine learning models in the research were able to accurately identify critical traits and predict both short-term (two-year) and long-term (five-year) survival outcomes for patients with ovarian cancer.

    Advancements and Broader Applicability

    Predictive Oncology has conducted research and collected and evaluated data to facilitate the identification and creation of new biomarkers for ovarian cancer. We will investigate these indicators further, both on our own and in conjunction with biopharma businesses. The business has previously shown the effectiveness of its machine learning platform by using a variety of patient samples from biobanks to accurately predict medication reactions.

    POAI is now advancing this process by applying state-of-the-art deep learning techniques for biomarker discovery related to patient overall survival (OS) and drug response. This platform enables the application of deep learning to appropriate patient cohorts, accelerating the initial stages of biomarker discovery.

    The identification of novel cancer biomarkers presents a significant opportunity for Predictive Oncology’s platform, leveraging the extensive value of its diverse patient samples and data. This also opens potential new revenue streams for the company.

    Market Potential

    Predictive Oncology’s technology holds broad applicability, including the development of clinical decision support tools for clinical trial screening and informing drug discovery and development. These capabilities extend beyond ovarian cancer, potentially aiding in the discovery of biomarkers for other cancer types.

  • Predictive Oncology Inc. (POAI) stock surged in the premarket trading sessions; here’s why

    Predictive Oncology Inc. (POAI) stock surged in the premarket trading sessions; here’s why

    Predictive Oncology Inc. (POAI stock) shares have shown advancement in the stock price in pre-market by 20.19% to trade at the price of $1.25 at the last check. POAI stock shed -4.59% while previously closing the session at $1.04. The POAI stock volume traded 2.39 million shares. POAI stock shed by-39.18% in the past year, and in the past week jumped up by 0.97%. In the past three and six months, the POAI stock has shed -7.14% and added 49.40% respectively. Furthermore, Predictive Oncology is currently valued at $67.93 million and has 48.80 million outstanding shares.

    What you need to know about Predictive Oncology Inc.

    Predictive Oncology Inc. is a medical instruments manufacturing company that delivers healthcare products and services of various sorts. The company’s manufacturing and supply platform has been established in the market of USA. There are three operational segments of the company which include Helomics, Soluble and Skyline.

    The company’s product and service offerings include environmentally conscious systems that target the infectious fluids’ collection and disposal. These infectious fluids are post-used and discarded after surgical procedures and operative cares.

    Company provides specifically provides a device for this targeting of fluid collection and disposal known as STREAMWAY system which is a wall mounted completely mechanized framework that arranges suction of fluid/liquid giving a continuous performance to doctors while essentially removing the possibility of medical services laborers’ vulnerability to infectious liquids gathered during careful and other patient strategies, as well as exclusive cleaning liquid and filters to clients of its system.

    The organization likewise gives contract research organization (CRO) and AI-driven prescient models of tumor drug reaction to work on clinical results to help drug, demonstrative, and biotech enterprises; and dissolvable and stable details for proteins, including immunizations, antibodies, and other protein therapeutics, just as creates tumor models for exactness malignancy treatment and medication improvement. Its CRO administrations improve the viability of malignant growth treatment utilizing the force of computerized reasoning (AI) applied to sicknesses information bases. The organization sells its clinical gadget items straightforwardly to emergency clinics and other clinical offices through utilized salespeople, self-employed entities, and wholesalers. The organization was once known as Precision Therapeutics Inc. furthermore, changed its name to Predictive Oncology Inc. in June 2019. Prescient Oncology Inc. was fused in 2002 and is situated in Eagan, Minnesota.

     

    Expansion and improvement in the product services of POAI stock’s subsidiaries thanks to GMP facilities

    Predictive Oncology Inc. is expanding its operational capacity and growing into a diverse and improved portfolio through its subsidiaries. Recently it announced that its two wholly owned subsidiaries are planning to expand through the qualification and fabrication of GMP facilities. These two subsidiaries are known as Soluble Biotech Inc. and Tumor Genesis Inc.

    This expansion will lead to increased potential of customer base as well as more qualified and attractive for the prospects of long term collaborations. This GMP facility will allow the company to be able to open the platform and opportunity for the researchers that are using cancer cell’s own mechanisms to use and produce a target which may be expressed protein or biological target.

    This is specifically done because the GMP facility allows for the company to provide formulations that are directly accessible to researchers for direct use in the lab. This facility acts as a bridge to shorten the manufacturing and supply process by directly providing a ready-made solution. GMP facility can also allow Soluble Biotech to provide its chromatography kits to biotech and biopharma companies as final protein purification step for animal and human testing and trial.